TransMedics Group, Inc. (NASDAQ: TMDX) is a Healthcare company (Medical - Devices) with a market capitalization of $3.3B. The Maz Rating grades it against the other companies in its sector.
TransMedics Group, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $93.91, TransMedics Group, Inc. trades at 22.2x trailing earnings, 4.5x sales and 5.9x book value, with an EV/EBITDA of 26.1. Over the last twelve months it generated about $732M of revenue and $147M of net income. It runs a gross margin of 58.6%, an operating margin of 11.9% and a net margin of 19.9%. It shows return on equity of 28.4%, return on invested capital of 6.1% and a free cash flow yield of 1.4%. On the balance sheet: a debt-to-equity ratio of 1.57 and a current ratio of 4.53. Over the past 52 weeks the share price ranged from $60.10 to $156.00, with a beta of 2.10.
TransMedics Group, Inc. does not currently pay a dividend.
13 Wall Street analyst ratings cover the stock: 9 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.